# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Argus Research analyst David Toung maintains Amgen (NASDAQ:AMGN) with a Buy and raises the price target from $300 to $340.
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatme...
RBC Capital analyst Gregory Renza maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $328 to $...